FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3047082589> ?p ?o ?g. }

• W3047082589 endingPage "1379" @default.
• W3047082589 startingPage "1368" @default.
• W3047082589 abstract "Purpose Esophageal cancer (EC) is an aggressive malignancy and is often resistant to currently available therapies. Inhibition of ribonucleotide reductase small subunit M2 (RRM2) in tumors is speculated to mediate chemosensitization. Previous studies have reported that Osalmid could act as an RRM2 inhibitor. We explored whether RRM2 was involved in radioresistance and the antitumor effects of Osalmid in EC. Methods and Materials RRM2 expression was detected by immunohistochemistry in EC tissues. The effects of Osalmid on cell proliferation, apoptosis, and cell cycle were assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphhenyl tetrazolium, colony formation, and flow cytometry assays. DNA damage, cell apoptosis, and senescence induced by Osalmid or ionizing radiation (IR) alone, or both, were detected with immunofluorescence, flow cytometry, Western blot, and β-galactosidase staining. A xenograft mouse model of EC was used to investigate the potential synergistic effects of Osalmid and IR in vivo. Results The expression of RRM2 in treatment-resistant EC tissues is much higher than in treatment-sensitive EC, and strong staining of RRM2 was correlated with shorter overall survival. We observed direct cytotoxicity of Osalmid in EC cells. Osalmid also produced inhibition of the ERK1/2 signal transduction pathway and substantially enhanced IR-induced DNA damage, apoptosis, and senescence. Furthermore, treatment with Osalmid and IR significantly suppressed tumor growth in xenograft EC models without additional toxicity to the hematologic system and internal organs. Conclusions Our study revealed that RRM2 played a vital role in radioresistance in EC, and Osalmid synergized with IR to exert its antitumor effects both in vitro and in vivo. Esophageal cancer (EC) is an aggressive malignancy and is often resistant to currently available therapies. Inhibition of ribonucleotide reductase small subunit M2 (RRM2) in tumors is speculated to mediate chemosensitization. Previous studies have reported that Osalmid could act as an RRM2 inhibitor. We explored whether RRM2 was involved in radioresistance and the antitumor effects of Osalmid in EC. RRM2 expression was detected by immunohistochemistry in EC tissues. The effects of Osalmid on cell proliferation, apoptosis, and cell cycle were assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphhenyl tetrazolium, colony formation, and flow cytometry assays. DNA damage, cell apoptosis, and senescence induced by Osalmid or ionizing radiation (IR) alone, or both, were detected with immunofluorescence, flow cytometry, Western blot, and β-galactosidase staining. A xenograft mouse model of EC was used to investigate the potential synergistic effects of Osalmid and IR in vivo. The expression of RRM2 in treatment-resistant EC tissues is much higher than in treatment-sensitive EC, and strong staining of RRM2 was correlated with shorter overall survival. We observed direct cytotoxicity of Osalmid in EC cells. Osalmid also produced inhibition of the ERK1/2 signal transduction pathway and substantially enhanced IR-induced DNA damage, apoptosis, and senescence. Furthermore, treatment with Osalmid and IR significantly suppressed tumor growth in xenograft EC models without additional toxicity to the hematologic system and internal organs. Our study revealed that RRM2 played a vital role in radioresistance in EC, and Osalmid synergized with IR to exert its antitumor effects both in vitro and in vivo." @default.
• W3047082589 created "2020-08-10" @default.
• W3047082589 creator A5009562294 @default.
• W3047082589 creator A5021520299 @default.
• W3047082589 creator A5032721322 @default.
• W3047082589 creator A5043958729 @default.
• W3047082589 creator A5053149189 @default.
• W3047082589 creator A5070551509 @default.
• W3047082589 date "2020-12-01" @default.
• W3047082589 modified "2023-10-02" @default.
• W3047082589 title "Osalmid, a Novel Identified RRM2 Inhibitor, Enhances Radiosensitivity of Esophageal Cancer" @default.
• W3047082589 cites W1898150109 @default.
• W3047082589 cites W1922694287 @default.
• W3047082589 cites W1973109316 @default.
• W3047082589 cites W1977127004 @default.
• W3047082589 cites W1990542495 @default.
• W3047082589 cites W1995580021 @default.
• W3047082589 cites W1997534577 @default.
• W3047082589 cites W2003601710 @default.
• W3047082589 cites W2050573392 @default.
• W3047082589 cites W2070555748 @default.
• W3047082589 cites W2071225892 @default.
• W3047082589 cites W2074576441 @default.
• W3047082589 cites W2085625938 @default.
• W3047082589 cites W2085946564 @default.
• W3047082589 cites W2088964752 @default.
• W3047082589 cites W2096439168 @default.
• W3047082589 cites W2099918668 @default.
• W3047082589 cites W2105202429 @default.
• W3047082589 cites W2111674123 @default.
• W3047082589 cites W2119587827 @default.
• W3047082589 cites W2122761469 @default.
• W3047082589 cites W2124512686 @default.
• W3047082589 cites W2140496330 @default.
• W3047082589 cites W2141689006 @default.
• W3047082589 cites W2165480504 @default.
• W3047082589 cites W2230150749 @default.
• W3047082589 cites W2234362807 @default.
• W3047082589 cites W2264676197 @default.
• W3047082589 cites W2276020348 @default.
• W3047082589 cites W2425235023 @default.
• W3047082589 cites W2551596349 @default.
• W3047082589 cites W2587858249 @default.
• W3047082589 cites W2591910005 @default.
• W3047082589 cites W2625452721 @default.
• W3047082589 cites W2742175805 @default.
• W3047082589 cites W2774872106 @default.
• W3047082589 cites W2885302348 @default.
• W3047082589 cites W2889308950 @default.
• W3047082589 cites W2903149622 @default.
• W3047082589 cites W2908769444 @default.
• W3047082589 cites W2912631429 @default.
• W3047082589 cites W2917837889 @default.
• W3047082589 cites W2937151884 @default.
• W3047082589 cites W2944112179 @default.
• W3047082589 cites W2981669912 @default.
• W3047082589 cites W4210685329 @default.
• W3047082589 doi "https://doi.org/10.1016/j.ijrobp.2020.07.2322" @default.
• W3047082589 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32763454" @default.
• W3047082589 hasPublicationYear "2020" @default.
• W3047082589 type Work @default.
• W3047082589 sameAs 3047082589 @default.
• W3047082589 citedByCount "11" @default.
• W3047082589 countsByYear W30470825892021 @default.
• W3047082589 countsByYear W30470825892022 @default.
• W3047082589 countsByYear W30470825892023 @default.
• W3047082589 crossrefType "journal-article" @default.
• W3047082589 hasAuthorship W3047082589A5009562294 @default.
• W3047082589 hasAuthorship W3047082589A5021520299 @default.
• W3047082589 hasAuthorship W3047082589A5032721322 @default.
• W3047082589 hasAuthorship W3047082589A5043958729 @default.
• W3047082589 hasAuthorship W3047082589A5053149189 @default.
• W3047082589 hasAuthorship W3047082589A5070551509 @default.
• W3047082589 hasConcept C104292427 @default.
• W3047082589 hasConcept C104317684 @default.
• W3047082589 hasConcept C126322002 @default.
• W3047082589 hasConcept C143425029 @default.
• W3047082589 hasConcept C150903083 @default.
• W3047082589 hasConcept C153911025 @default.
• W3047082589 hasConcept C186000732 @default.
• W3047082589 hasConcept C190283241 @default.
• W3047082589 hasConcept C203014093 @default.
• W3047082589 hasConcept C206684579 @default.
• W3047082589 hasConcept C207001950 @default.
• W3047082589 hasConcept C2776415932 @default.
• W3047082589 hasConcept C29537977 @default.
• W3047082589 hasConcept C4710235 @default.
• W3047082589 hasConcept C502942594 @default.
• W3047082589 hasConcept C509974204 @default.
• W3047082589 hasConcept C552990157 @default.
• W3047082589 hasConcept C553184892 @default.
• W3047082589 hasConcept C55493867 @default.
• W3047082589 hasConcept C58962609 @default.
• W3047082589 hasConcept C62112901 @default.
• W3047082589 hasConcept C71924100 @default.
• W3047082589 hasConcept C86803240 @default.
• W3047082589 hasConceptScore W3047082589C104292427 @default.
• W3047082589 hasConceptScore W3047082589C104317684 @default.

• next